Get the Stockscreener App
6.18
0.16%
-0.01
After Hours:
6.18
Certara Inc stock is traded at $6.18, with a volume of 1.71M.
It is down -0.16% in the last 24 hours and up +14.23% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
See More
Previous Close:
$6.19
Open:
$6.17
24h Volume:
1.71M
Relative Volume:
0.47
Market Cap:
$947.55M
Revenue:
$418.84M
Net Income/Loss:
$-1.60M
P/E Ratio:
-600.00
EPS:
-0.0103
Net Cash Flow:
$69.77M
1W Performance:
+0.65%
1M Performance:
+14.23%
6M Performance:
-46.59%
1Y Performance:
-51.64%
1-Day Range:
$6.01
$6.25
1-Week Range:
$5.81
$6.32
52-Week Range:
$5.19
$13.88
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, BTSG, TEM, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
6.18 | 949.08M | 418.84M | -1.60M | 69.77M | -0.0103 |
VEEV
Veeva Systems Inc
|
171.19 | 27.80B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
51.44 | 10.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
54.07 | 10.01B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.63 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.77 | 4.60B | 637.78M | 239.40M | 307.21M | 1.1909 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-27-26 | Downgrade | Craig Hallum | Buy → Hold |
| Jan-06-26 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-21-25 | Initiated | Rothschild & Co Redburn | Buy |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-29-25 | Initiated | Craig Hallum | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-08-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Certara (CERT) Sells Regulatory and Medical Writing Business for Up to $135M - Yahoo Finance
Veristat expands with Certara acquisition - BioXconomy
Certara (CERT) price target decreased by 23.74% to 9.63 - MSN
AI in Predictive Toxicology Research Report 2026 Featuring - GlobeNewswire
AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, ChemaxonGlobal Forecast to 2030 and 2035 - Yahoo Finance
Certara strategic business divestiture comes at right time, says analyst - MSN
Certara | D: Filing D - Moomoo
Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight - GlobeNewswire Inc.
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates - MSN
Certara to sell regulatory and medical writing business for up to $135M - MSN
How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations - Yahoo Finance
Wall Street analysts think Certara (CERT) could surge 43.28%: Read this before placing a bet - MSN
Certara: An Interesting Situation To Keep Track Off (NASDAQ:CERT) - Seeking Alpha
CERT Price Today: Certara, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
(CERT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Barclays Remains a Hold on Certara (CERT) - The Globe and Mail
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst - Sahm
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report? - MSN
CERT Certara posts 8.8 percent year-over-year Q4 2025 revenue growth despite sizeable EPS miss pressuring shares.Barrier to Entry - UBND thành phố Hải Phòng
Certara to Divest Regulatory and Medical Writing Business - The Globe and Mail
Certara to sell regulatory writing unit to Veristat for $135M By Investing.com - Investing.com India
Is Certara (CERT) stock considered stable (+2.26%) 2026-04-22Price Surge - Cổng thông tin điện tử tỉnh Lào Cai
Certara (CERT) Sells Regulatory Writing Business for Up to $135 Million - GuruFocus
Veristat to Acquire Certara’s Regulatory and Medical Writing Business - Business Wire
William Blair Maintains Certara(CERT.US) With Hold Rating - Moomoo
Veristat, LLC signed a definitive agreement to acquire Regulatory and Medical Writing business of Certara, Inc for approximately $140 million. - marketscreener.com
Craig-Hallum Initiates Certara(CERT.US) With Hold Rating - Moomoo
Certara Shares Rise Amid Plan to Sell Portion of Business to Veristat - Moomoo
Certara to Sell Regulatory and Medical Writing Business to Veristat for Up to $135 Million, Refocuses on Model-Informed Drug Development 1 - Minichart
Certara to sell regulatory writing unit to Veristat for $135M - Investing.com
Certara to Sell Regulatory, Medical Writing Business to Veristat for $135 Million - marketscreener.com
Certara : Regulatory and Medical Writing – Supplemental Information - marketscreener.com
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat - The Manila Times
Certara to Sell Global Medical Writing Business to Veristat for $100M, Plus Up to $35M Earn-Out - TradingView
Certara (NASDAQ: CERT) divests regulatory and medical writing unit to Veristat - Stock Titan
Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH) - The Globe and Mail
Certara, Inc. $CERT Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):